Ajouter à votre calendrierDiscovery of new drug combinations for epigenetic therapy of cancer
Epigenetic drugs, such as DNA methylation inhibitors (DNMTi) or histone deacetylase inhibitors (HDACi), are approved in monotherapy for cancer treatment. These drugs reprogram gene expression profiles, reactivate tumor suppressor genes (TSG) producing cancer cell differentiation and apoptosis. Epigenetic drugs have been shown to synergize with other epigenetic drugs or various anticancer drugs. To discover new molecular entities that enhance epigenetic therapy, we performed a high-throughput screening using FDA-approved libraries in combination with DNMTi or HDACi. We discovered that 45 FDA-approved drugs of different classes enhanced DNMTi and HDACi activity, suggesting the combination in the clinics.
Noël J-M RAYNAL, M.Sc. Ph.D.
Professeur sous-octroi adjoint, Département de pharmacologie et physiologie, Université de Montréal
Chercheur, Axe Maladies virales, immunitaires et cancers, Centre de recherche du CHU Sainte-Justine